Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 5;20(1):519.
doi: 10.1186/s12885-020-06847-9.

Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck

Thomas J W Klein Nulent  1   2 , Matthijs H Valstar  3   4 , Laura A Smit  5 , Ludwig E Smeele  3   4 , Nicolaas P A Zuithoff  6 , Bart de Keizer  7 , Remco de Bree  8 , Robert J J van Es  8   9 , Stefan M Willems  10
Affiliations

Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck

Thomas J W Klein Nulent et al. BMC Cancer. .

Abstract

Background: Treatment options for advanced head and neck adenoid cystic carcinoma (AdCC) are limited. Prostate-Specific Membrane Antigen (PSMA), a transmembrane protein that is known for its use in diagnostics and targeted therapy in prostate cancer, is also expressed by AdCC. This study aimed to analyse PSMA expression in a large cohort of primary, recurrent and metastasized AdCC of the head and neck.

Methods: One hundred ten consecutive patients with histologically confirmed AdCC in the period 1990-2017 were included. An analysis was made of clinical details, revised pathology and semiquantitative immunohistochemical expression of PSMA on tissue microarray and whole slides. Associations of PSMA expression with clinicopathological parameters were explored and survival was analysed by multivariate Cox-proportional Hazard analysis.

Results: PSMA expression was present in 94% of the 110 primary tumours, with a median of 31% positive cells (IQR 15-60%). Primary tumours (n = 18) that recurred (n = 15) and/or had metastases (n = 10) demonstrated 40, 60 and 23% expression respectively. Expression was not independently related to increased pathological stage, tumour grade, and the occurrence of locoregional recurrence or metastasis. After dichotomization, only primary tumour PSMA expression ≤10% appeared to be associated with reduced 10-years recurrence-free survival (HR 3.0, 95% CI 1.1-8.5, p = .04).

Conclusions: PSMA is highly expressed in primary, recurrent and metastatic AdCC of the salivary and seromucous glands. PSMA expression has no value in predicting clinical behaviour of AdCC although low expression may indicate a reduced recurrence-free survival. This study provides supporting results to consider using PSMA as target for imaging and therapy when other diagnostic and palliative treatment options fail.

Keywords: Adenoid cystic carcinoma; Immunohistochemistry; PSMA; Prostate-specific membrane antigen; Salivary gland neoplasms; Survival analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Representative immunohistochemical PSMA expression in primary and metastatic AdCC showing variation in the number of positive staining tumour cells. a nasal cavity; 5%; magnification 200x.b submandibular gland; 90%; magnification 400x.c pulmonary metastasis; 70%; magnification 200x.d bone metastasis; 5%; magnification 200x
See this image and copyright information in PMC

References

    1. Horoszewicz JS, Kawinsky EMG. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–935. - PubMed
    1. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–1811. - PubMed
    1. Wright GL, Haley C, Lou BM, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol Semin Orig Investig. 1995;1:18–28. doi: 10.1016/1078-1439(95)00002-Y. - DOI - PubMed
    1. Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–6362. - PubMed
    1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–1705. doi: 10.2967/jnumed.115.161299. - DOI - PubMed

MeSH terms